Pharmaxis (ASX:PXS) has appointed Dr Kathleen Metters as a non-executive director on the company, bringing more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases.
Pharmaxis is focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
Dr Metters spent nine years as a senior executive with Merck & Co., which included a 4 year period as senior vice president and head of Worldwide Basic Research.
Malcolm McComas, chairman, commented:
"The appointment of Dr Metters to the Pharmaxis board follows a global search for a candidate who could contribute to the Pharmaxis business model of creating value through excellence in drug discovery and development.
"Her distinguished career in drug discovery inside a major multinational Pharma company and more recent role as a CEO of a smaller biotech company gives Dr Metters the experience and insight to make a significant contribution to Pharmaxis.
"We are delighted to welcome her to the board at a time when we are making significant steps forward with our pipeline of anti-inflammatory and anti-fibrotic therapies and progressing our aim to building a globally competitive company."